Manufacturing and Automation
As regenerative medicine products evolve, regulation is clarifying the requirements of platforms to deliver the medicines to the patient and systems for the manufacture and supply of the products. The EPSRC Centre addresses the challenges of the straightforward, consistent, cost effective supply of cellular therapies by developing tools and technologies that will equip the growing industry.
Characterisation and Control
The regenerative medicine industry requires the manufacture of high quality medical products at an economically acceptable cost. The safe and reproducible delivery of a commercially viable and clinically effective regenerative medicine product is key to its success. In-process characterisation of the cell component, scaffold and combined product will allow efficient and precise process development and will enable process analytical technology for manufacture to be selected on the basis of the most useful data. Rapid identification of deviation during manufacture will allow a corrective in-process response to be made, reducing failure rates and decreasing the dependence on end-product testing; this will positively impact both risk and cost of manufactured product.
Delivery and 3D products
The delivery of cells to the patient in a clinical setting raises scientific and technological challenges. Simple injection of cell suspensions into a disease site is inefficient, resulting in wastage of cells, compromised viability of the medicine and poor starting conditions for the regeneration of the target tissue. The EPSRC Centre investigates the development of materials to aid cell delivery to the target tissue, with a particular focus on the challenges of creating reproducible 3D scaffolds.